SUWANEE, Ga., April 20, 2018 -- Digirad Corporation (NASDAQ:DRAD) will release financial results for its first quarter ended March 31, 2018, before the market opens on Tuesday, May 1, 2018.
A conference call is scheduled for 11:00 a.m. EDT (8:00 a.m. PDT) on May 1, 2018 to discuss the results and management’s outlook. The call may be accessed by dialing 1-877-407-9039 (international callers +1-201-689-8470). A simultaneous webcast of the call may be accessed online from the Events & Presentations link on the Investor Relations page of the Digirad website at http://drad.client.shareholder.com; an archived replay of the webcast will be available within 15 minutes of the end of the conference call.
About Digirad Corporation
Digirad delivers convenient, effective, and efficient healthcare solutions on an as needed, when needed, and where needed basis. Digirad’s diverse portfolio of mobile healthcare solutions and diagnostic imaging equipment and services, provides hospitals, physician practices, and imaging centers throughout the United States access to technology and services necessary to provide exceptional patient care in the rapidly changing healthcare environment. For more information, please visit www.digirad.com.
Forward-Looking Statements
This press release contains statements that are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995. Some of these forward-looking statements can be identified by the use of forward-looking words such as “believes,” “expects,” “may,” “will,” “should,” “seek,” “approximately,” “intends,” “plans,” “estimates,” or “anticipates,” or the negative of those words or other comparable terminology, or in specific statements such as the Company’s ability to deliver value to customers, the ability to grow and generate positive cash flow, the ability to execute on restructuring activities, and ability to successfully execute acquisitions. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from the statements made. These risks are detailed in Digirad’s filings with the U.S. Securities and Exchange Commission, including the Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other reports. Readers are cautioned to not place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Digirad undertakes no obligation to revise or update the forward-looking statements contained herein.
| For more information contact: |
| Matt Molchan |
| President & CEO |
| 858-726-1600 |
| [email protected] |


Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims
Bain Capital Secures RBI Approval to Acquire Up to 41.7% Stake in Manappuram Finance
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal
Grok AI Market Share Surges as xAI Faces Scrutiny Over Image Generation Controversy
Westpac (ASX: WBC) Q1 Profit Rises 6% as Lending Growth and Treasury Income Strengthen Earnings
How Marco Pharma International Preserves German Homeopathic Traditions in America
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App
Anduril Eyes $60 Billion Valuation in New Funding Round to Expand Defense Manufacturing and Autonomous Fighter Jet Development
FTC Questions Apple News Over Alleged Bias Against Conservative Media
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute
Lockheed Martin Secures $101M in U.S. Defense Contracts for AEGIS, F-35, and Missile Systems
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed
Bank of America CEO Brian Moynihan’s 2025 Compensation Rises 17% to $41 Million Amid Strong Profit Growth
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 



